Updates

Announcements

Audited Report & Accounts published on website

Apr 30, 2020

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Audited Annual Report and Accounts (“Report”) for the year ended 31 December 2019, has today been published on the Company’s website. Copies of this Report, including the Notice of Annual General Meeting, will be posted to shareholders in…
FINAL RESULTS For the 12 months ended 31 December 2019

Apr 30, 2020

ImmuPharma plc (LSE:IMM), (Euronext Growth Brussels: ALIMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2019 (the “Period”). Key Highlights (including post Period review) Stable financial performance over the Period – Cash balance of £1.4 million (31 December 2018: £4.9…
ImmuPharma to present live on ‘Investor Meet Company’ platform Tuesday 7 April 2020 | 10.30am (BST)

Apr 6, 2020

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), a specialist drug discovery and development company, is pleased to announce that Tim McCarthy, Chairman of ImmuPharma, will provide a live presentation relating to the recently announced (30/3/20) £1.5 million Subscription and update on the Company’s R&D programmes, via the ‘Investor Meet Company’ platform. The live…
TR1 – Notification of major interest in shares by Lanstead Capital – 3 April 2020

Apr 3, 2020

TR1 – Notification of major interest in shares by Lanstead Capital – 3 April 2020 To view document click here
TR1 – Notification of major interest in shares from Robert Zimmer – 2 April 2020

Apr 3, 2020

TR1 – Notification of major interest in shares from Robert Zimmer – 2 April 2020 To view document click here
Subscription to raise £1.5 million to fund expansion of R&D pipeline

Mar 30, 2020

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), the specialist drug discovery and development company, is pleased to announce subscriptions to raise £1.5 million (the “Subscriptions”) through the issue of 15,000,000 new ordinary share of 10 pence each in the Company (“Ordinary Shares”) (the “Subscription Shares”) at a price of 10p per Ordinary Share…
Incanthera plc – Admission to trading on the NEX Exchange Growth Market Publication of Admission Document

Feb 28, 2020

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), a specialist drug discovery and development company, notes that further to its announcement on 17 February 2020, Incanthera plc (“Incanthera”), a specialist oncology company, has today been admitted to the NEX Exchange Growth Market (TIDM: INC) and has published its Admission Document. Following Admission to trading,…
Oncology specialist Incanthera, in which ImmuPharma currently has a 14.0% shareholding, announces Rule 23 Notice in advance to quoting on NEX Exchange Growth Market

Feb 17, 2020

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), a specialist drug discovery and development company, notes that the NEX Exchange Growth Market (“NEX”) has today released a pre-admission announcement under Rule 23 of the intention of Incanthera plc (“Incanthera”), a specialist oncology company, to quote on NEX. ImmuPharma currently holds a 14.0% shareholding in…
ImmuPharma provides an update on the Avion Agreement in relation to Lupuzor’s™ new international Phase III trial

Feb 6, 2020

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), a specialist drug discovery and development company, announces an update on activities with Avion Pharmaceuticals LLC (“Avion”) following the successful licence and development agreement signed with Avion in November 2019 for the exclusive rights to Lupuzor™ in North America (United States). A summary of key activities…
Admission to trading on Euronext Growth Brussels

Dec 19, 2019

ImmuPharma PLC (LSE:IMM | Euronext Growth: ALIMM), a specialist drug discovery and development company, is pleased to announce that, this morning at approximately 09.00am (GMT), ImmuPharma will commence trading on Euronext Growth Brussels (“Euronext”) under ticker ‘ALIMM’. This new listing does not affect the trading of ImmuPharma’s shares on AIM, nor is there any intention…
Publication of Information Note – In advance to admission to trading on Euronext Growth Brussels

Dec 17, 2019

ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, is pleased to announce that, further to the announcement of 13 December 2019, that its shares will be admitted to trading on Euronext Growth Brussels (“Euronext”) under ticker ‘ALIMM’, it has today published the Information Note, as required by the Euronext Growth Market Rules Book…
Dual listing on Euronext growth Brussels

Dec 13, 2019

ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company is pleased to announce that its shares will be admitted to trading on Euronext Growth Brussels (“Euronext”) under ticker ‘ALIMM’ following the approval by Euronext of its request for listing. Admission is expected to take effect from 19 December 2019. This new listing does not…
Share price volatility

Dec 11, 2019

ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that following the recently announced licensing and development agreement with Avion, the US speciality pharmaceutical company, in which Avion will fund an international Phase III trial for our lead programme, Lupuzor™, we note the volatility in the Company’s share price and speculation concerning a…
ImmuPharma to present at Biotech Showcase™ 2020 in San Francisco

Dec 3, 2019

ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, is pleased to announced that it will be presenting at the Biotech Showcase™ 2020, to be held between 13–15 January 2020, at the Hilton, San Francisco Union Square. Dr Tim Franklin, Commercial Advisor to ImmuPharma, will be presenting to conference attendees on 14th January 2020…
TR1 – Notification of major interest in shareholdings

Dec 2, 2019

TR1 – Notification of major interest in shareholdings Please click here
ImmuPharma and Avion Pharmaceuticals sign exclusive licence

Nov 28, 2019

ImmuPharma and Avion Pharmaceuticals sign exclusive licence and development agreement and trademark agreement for Lupuzor™ with Avion to fund new international Phase III trial and commercialise in the US ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces a licence and development agreement with Avion Pharmaceuticals LLC, for the exclusive rights to Lupuzor™…
INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2019

Sep 30, 2019

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2019 (the “Period”). Key Highlights (including post Period review) Financials Stable financial performance over the Period – Cash balance of £2.3 million as at 30 June 2019 (31 December…
TR1 – Notification of Major Interest – Lanstead Capital Investors

Jul 4, 2019

For further information click here
TR1 – Notification of Major Shareholding

Jul 2, 2019

For full information click here
2019 Annual General Meeting – All resolutions passed

Jun 28, 2019

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.
Primary endpoint successfully met from the open label extension study evaluating safety and tolerability from the Pivotal Phase III trial of Lupuzor™ in patients with Systemic Lupus Erythematosus (“Lupus”)

Jun 28, 2019

Study demonstrates robust safety profile of Lupuzor™ with no ‘serious adverse events’ reported ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce analysis of the results from the open label six month extension study from its original Pivotal Phase III trial of Lupuzor™, its lead programme for the potential breakthrough…

2025 (24)

2024 (19)

2023 (25)

2022 (27)

2021 (21)

2020 (40)

2019 (19)

2018 (22)

2017 (17)

2016 (25)

2015 (17)

2014 (12)

2011 (2)

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MBA

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Dr Tim Franklin PhD, MBA

Chief Operating Officer

Tim has 30 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Dr Laura Mauran-Ambrosino Ph.D.

Head of R&D

Born in Montpellier, France, Dr Mauran- Ambrosino obtained her PhD in Chemistry at the Université de Bordeaux as a CIFRE fellow in co-supervision by Dr Goudreau.

She then conducted postdoctoral studies at the “Centre Hospitalier Universitaire” Pellegrin in cell biology. In 2018, she joined Ureka and established the biology department and the analytical chemistry department and in 2021, she became Chief Scientific Officer of Ureka Pharma. Dr Mauran-Ambrosino was a key contributor to the development of BioGlucagon, and BioAMB.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a NSERC fellow before moving to Switzerland to conduct postdoctoral studies at the ETH Zürich as an FRQNT fellow. He then moved back to Canada for one year where he co-founded FindMolecule inc. and worked for the pharma industry.

In 2014 he joined ImmuPharma as research director and established the research laboratories of Ureka in Bordeaux. After the merger of ELRO with Ureka in 2019, Dr Goudreau became Chief Scientific Officer of Ureka Pharma and in 2021, he became Chief Executive Officer of ImmuPharma Biotech. Notably, Dr Goudreau and his team are credited for the discovery and development of, among others, URK 614, BioGlucagon, and BioAMB.

Tim McCarthy FCCA, MBA

Chief Executive Officer

Tim has 40 years’ international senior level business experience in high growth biotech, healthcare and technology companies. He is also Chairman of Incanthera plc. Tim was formerly Chairman of 4basebio plc and CEO and CFO of a number of UK public listed and private companies including, Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

Announcements

Audited Report & Accounts published on website

FINAL RESULTS For the 12 months ended 31 December 2019

ImmuPharma to present live on ‘Investor Meet Company’ platform Tuesday 7 April 2020 | 10.30am (BST)

TR1 – Notification of major interest in shares by Lanstead Capital – 3 April 2020

TR1 – Notification of major interest in shares from Robert Zimmer – 2 April 2020

Subscription to raise £1.5 million to fund expansion of R&D pipeline

Incanthera plc – Admission to trading on the NEX Exchange Growth Market Publication of Admission Document

Oncology specialist Incanthera, in which ImmuPharma currently has a 14.0% shareholding, announces Rule 23 Notice in advance to quoting on NEX Exchange Growth Market

ImmuPharma provides an update on the Avion Agreement in relation to Lupuzor’s™ new international Phase III trial

Admission to trading on Euronext Growth Brussels

Publication of Information Note – In advance to admission to trading on Euronext Growth Brussels

Dual listing on Euronext growth Brussels

Share price volatility

ImmuPharma to present at Biotech Showcase™ 2020 in San Francisco

TR1 – Notification of major interest in shareholdings

ImmuPharma and Avion Pharmaceuticals sign exclusive licence

INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2019

TR1 – Notification of Major Interest – Lanstead Capital Investors

TR1 – Notification of Major Shareholding

2019 Annual General Meeting – All resolutions passed

Primary endpoint successfully met from the open label extension study evaluating safety and tolerability from the Pivotal Phase III trial of Lupuzor™ in patients with Systemic Lupus Erythematosus (“Lupus”)